Total amount: € 0,00
HOW TO ORDER
THE JOURNAL OF CARDIOVASCULAR SURGERY
A Journal on Cardiac, Vascular and Thoracic Surgery
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632
The Journal of Cardiovascular Surgery 2016 Apr 14
Comparison of peri-procedural and mid-term stroke rates and outcomes between surgical aortic valve replacement and transcatheter aortic valve replacement patients: a single center real world experience
Seyed H. AALAEI-ANDABILI 1, R. David ANDERSON 2, John W. PETERSEN 2, Thomas M. BEAVER 1, Anthony A. BAVRY 2, 3, Charles T. KLODELL 1 ✉
1 Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Florida, Gainesville, Florida, USA; 2 Division of Cardiology, Department of Medicine, University of Florida, Gainesville, Florida, USA; 3 North Florida, South Georgia Veterans Health System, Gainesville, FL
BACKGROUND: We compared stroke occurrence and outcomes between Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR), both peri-procedural and at follow-up.
METHODS: 391 consecutive patients (March2012-December2014) underwent TAVR (n=290) or isolated SAVR (n=101), concomitantly. Patients’ data were prospectively collected.
RESULTS: TAVR patients had more comorbidities. One (0.34%) TIA and 9 (3.11%) strokes occurred in-hospital following TAVR, but no cerebrovascular event occurred after SAVR (p=0.11). One stroke (0.99%) and one TIA (0.99%) were detected in SAVR group within 30- days. Among TAVR patients, one (0.75%) stroke at 6-months, 2 (1.9%) strokes and 2 (1.9%) TIAs at 12-month were diagnosed. Kaplan-Meier analysis revealed that 96% and 99% 12-month CVA free survival following TAVR and SAVR, respectively (p=0.67). Pre-operative mean trans- aortic valve systolic pressure gradient higher than 40 mmHg remained as risk factor for stroke in TAVR patients only, OR: 4.48 (CI: 1.2-16.54, p=0.02). One intraoperative death, and 5 (4 with CVA) in-hospital deaths occurred after TAVR; whereas only one patient died in SAVR group (p=0.49). Thirty-day mortality was 3.8% (11/290) for TAVR and 0.99% (1/101) for SAVR patients. SAVR patients’ survival was 99% at 6 months, 97.9% at 12, and 96.4% at 24 months, whereas survival in TAVR was 97.5% at 6, 92% at 12, and 73.6% at 24 months (HR: 8.43 (CI: 2.47-28.73), p<0.001).
CONCLUSIONS: Even with significant differences in patients’ baseline characteristics; in-hospital and mid-term stroke rates are not significantly higher following TAVR than SAVR. Although peri-procedural stroke is not uncommon in TAVR, mid-term stroke rate is low.